Predictive Impact of Urokinase-Type Plasminogen Activator: Plasminogen Activator Inhibitor Type-1 Complex on the Efficacy of Adjuvant Systemic Therapy in Primary Breast Cancer

Cancer Research

Volumn 64, Issue 2, 2004, Pages 659-664

  Manders, Peggy ^a   Tjan Heijnen, Vivianne C G ^a   Span, Paul N ^a   Grebenchtchikov, Nicolai ^a   Foekens, John A ^b   Beex, Louk V A M ^a   Sweep, C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; TAMOXIFEN; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COMPLEX FORMATION; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, PROGESTERONE; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 1642475133     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1820     Document Type: Article

References (30)

1. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
2. Schmitt, M., Harbeck, N., Thomssen, C., Wilhelm, O., Magdolen, V., Reuning, U., Ulm, K., Höfler, H., Jänicke, F., and Graeff, H. Clinical impact of the plasminogen activation system I tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost., 78: 285-296, 1997.
3. Duffy, M. J., Maguire, T. M., McDermott, E. W., and O'Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol., 71: 130-135, 1999.
4. r 55,000 form of the plasminogen activator, urokinase. J. Cell Biol., 100: 86-92, 1983.
5. Cubellis, M. V., Nolli, M. L., Cassani, G., and Blasi, F. Binding of single-chain prourokinase receptor to human U937 cells. J. Biol. Chem., 261: 15819-22, 1986.
6. Conese, M., and Blasi, F. Urokinase/urokinase receptor system: internalization/ degradation of urokinase-serpin complexes: mechanisms and regulation. Biol. Chem. Hoppe-Seyler, 376: 143-155, 1995.
7. Rijken, D. C. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillière's Clin. Haematol., 8: 291-312, 1995.
8. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
9. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Van Meijer-Gelder, M. E., Henzen-Logmans, S. C., Van Putten, W. L., and Klijn, J. G. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res., 60: 636-643, 2000.
10. Look, M. P., Van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Fernö, M., Eppenberger-Castori, S., Sweep, C. G. J., Ulm, K., Peyrat, J. P., Martin, P. M., Magdelenat, H., Brünner, N., Duggan, C., Lisboa, B. W., Bendahl, P. O., Quillien, V., Daver, A., Ricolleau, G., Van Meijer-Gelder, M. E., Manders, P., Ficts, W. E., Blankenstein, M. A., Broë, P., Romain, S., Daxenbichler, G., Windbichler, G., Cufer, T., Borstnar, S., Kueng, W., Beex, L. V. A. M., Klijn, J. G. M., O'Higgins, N., Eppenberger, U., Jänicke, F., Schmitt, M., and Foekens, J. A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst., 94: 116-128, 2002.
11. Jänicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J., Selbmann, H. K., Graeff, H., and Schmitt, M. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst., 93: 913-920, 2001.
12. Pierga, J. Y., Laine-Bidrom, C., Beuzeboc, P., DeCremoux, P., Pouillart, P., and Magdelenat, H. Plasminogen-activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant CT in breast cancer. Br. J. Cancer, 76: 537-540, 1997.
13. Foekens, J. A., Look, M. P., Peters, H. A., van Putten, W. L. J., Portengen, H., and Klijn, J. G. M. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst., 87: 751-756, 1995.
14. Harbeck, N., Kates, R. E., and Schmitt, M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol., 20: 1000-1007, 2002.
15. Harbeck, N., Kates. R. E., Look, M. P., Meijer-van Gelder, M. E., Klijn, J. G., Kruger, A., Kiechle, M., Janicke, F., Schmitt, M., and Foekens, J. A. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res., 62: 4617-4622, 2002.
16. Hekman, C. M., and Loskutoff, D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem., 260: 11581-7, 1985.
17. Witte, J. H. de, Sweep, C. G. J., Klijn, J. G., Grebenschikov, N., Peters, H. A., Look, M. P., Tienoven, T. H. van, Heuvel, J. J., Bolt-Vries, J. de, Benraad, T. J., and Foekens, J. A. Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer. Br. J. Cancer, 80: 286-294, 1999.
18. Manders, P., Beex, L. V. A. M., Tjan-Heijnen, V. C. G., Geurts-Moespot, J., van Tienoven, T. H., Foekens, J. A., and Sweep, C. G. J. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer, 87: 772-778, 2002.
19. Koenders, A. J. M., Geurts-Moespot, A., Zollingen, S., and Benraad, Th. Progesterone and estradiol receptors in DMBA-induced mammary tumors before and after ovariectomy and after subsequent estradiol administration. In: W. McGuire, J. Raynaud, and E. Baulieu (eds.), Progesterone Receptors in Normal and Neoplastic Tissues (Progress in Cancer and Therapy), pp. 71-84. New York, NY: Raven Press, 1977.
20. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurements with the folin reagent. J. Biol. Chem., 193: 265-275, 1951.
21. Grebenschikov, N., Geurts-Moespot, A., de Witte, H., Heuvel, J., Leake, R., Sweep, F., and Benraad, T. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI-1) in breast tumor cytosols. Int. J. Biol. Markers. 12: 6-14, 1997.
22. Grebenschikov, N., Sweep, F., Geurts, A., Andreasen, P., de Witte, H., Schousboe, S., Heuvel, J., and Benraad, T. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int. J. Cancer, 81: 598-606, 1999.
23. Sweep, C. G. J., Geurts-Mocspot, J., Grebenschikov, N., de Witte, J. H., Heuvel, J. J., Schmitt, M., Duffy, M. J., Jänicke, F., Kramer, M. D., Foekens, J. A., Brunner, N., Brugal, G., Pedersen, A. N., and Benraad, T. J. External quality assessment of trans-European multicenter antigen determination (enzyme-linked immunosorbent assay) of urokinase plasminogen activator (uPA) and its type-1) inhibitor (PAI-1) in human breast cancer extracts. Br. J. Cancer, 78: 1434-1441, 1998.
24. Cox, D. R. Regression models and life-tables. J. R. Statist. Soc. B., 34: 187-220, 1972.
25. Simon, R., and Altman. D. G. Statistical aspects of prognostic factor studies in oncology. Br. J. Cancer, 69: 979-985, 1994.
26. Goldhirsch, A., Glick. J. H., Gelber, R. D., Coates, A. S., and Senn, H.-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J. Clin. Oncol., 19: 3817-3827. 2001.
27. Benraad, T. J., Geurts-Moespot, J., Grøndahl-Hansen, J., Schmitt, M., Heuvel, J. J., de Witte, J. H., Foekens, J. A., Leake, R. E., Brünner, N., and Sweep, C. G. J. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-I workshop. Eur. J. Cancer, 32A: 1371-1381, 1996.
28. Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., Andresen, P. B., Kristensen, P., and Danø, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 752-757, 1984.
29. Kielberg, V., Andreasen, P. A., Grondahl-Hansen, J., Nielsen, L. S., Skriver, L., and Danø, K. Proenzyme to urokinase-type plasminogen activator in the mouse in vivo. FEBS Lett., 182: 441-445, 1985.
30. Witte, J. H. de, Sweep, C. G. J., Klijn, J. G., Grebenschikov, N., Peters, H. A., Look, M. P., Tienoven, T. H. van, Heuvel, J. J., Putten, W. L. van, Benraad, T. J., and Foekens, J. A. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. Br. J. Cancer, 79: 1190-1198, 1999.